Project Grant R01CA289606
Award Date 12/15/24
Completion Date 11/30/29
Dollars Obligated $688K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) supports an integrated in silico and in vivo genetic screening approach to identify subtype-specific genetic dependencies in hepatocellular carcinoma (HCC). The $104,096 award, effective December 1, 2025, will be used by the University of Pittsburgh to determine whether dependencies predicted via deep learning demonstrate subtype specificity using in vivo loss-of-function screening. The project...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $634,061 to the University of Maryland, Baltimore to study the role of tumor-associated plasmacytoid dendritic cells (TAPDC) in the tumor immune microenvironment (TIME) of liver cancer or hepatocellular carcinoma (HCC) during HIV infection. The 5-year project aims to: 1) Characterize how TAPDC reprogram the HCC TIME in HCC-HIV mouse models and human samples; 2) Define how TAPDC modulate...
- This $521,579 Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research to identify critical regulators controlling clear cell renal cell carcinoma (CCRCC) lung metastasis. The University of Texas Southwestern Medical Center, the awardee, will conduct a genome-wide CRISPR screen to characterize the role of the hepatic leukemia factor (HLF) in CCRCC lung metastasis and examine the underlying molecular...
- The National Cancer Institute (NCI) awarded a $793,324 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Beckman Research Institute of the City of Hope to develop selective small molecule inhibitors against the CYP8B1 enzyme as a novel therapeutic approach for treating hepatocellular carcinoma (HCC), including metabolic dysfunction-associated HCC. The 3-year project, running from Apr 2025 to Mar 2028, aims to discover and validate CYP8B1 inhibitors as probes to target HCC, which...
- This $399,966 Project Grant was awarded on June 23, 2025 by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396). The grant supports the pre-clinical development of a novel therapeutic approach by Cloverleaf Bio, Inc. to treat hepatocellular carcinoma (HCC), the most common form of liver cancer. The research aims to develop engineered transfer RNAs (tRNAs) containing the chemotherapeutic agent 5-fluorouracil (5-FU) to irreversibly inhibit multiple...
- This federal Project Grant award of $306,739 from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), aims to improve treatment outcomes for liver cancer (hepatocellular carcinoma, HCC) patients. The research focuses on identifying the most effective inhibitors of the enzyme ENPP1 in HCC models, as ENPP1 plays a key role in suppressing the immune response against HCC tumors. The grantee, Riboscience LLC, will utilize their lead ENPP1 inhibitor compound...
- This $165,883 Project Grant award, funded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports a research project led by Dr. Xinyuan (Cindy) Zhang at Brigham & Women's Hospital (a subsidiary of Partners Healthcare System) to investigate inflammation and hepatocellular carcinoma (HCC). The key objectives of this 2-year project are to: 1) use computational and system biology approaches to examine pre-diagnostic plasma proteomics of HCC cases compared to...
- This $194,914 Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) supports research by the University of Texas Health Science Center at Houston (UTHealth) on modeling the activation of oncogenes in cancer through genome engineering and single-cell sequencing. The central hypothesis is that quantitative oncogene expression modeling should incorporate the variable binding of transcription factors and promoter sequences, in addition to...
- This Project Grant award, valued at $593,042.00, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The award will support research by The Leland Stanford Junior University (Stanford University) to investigate the role of the complement pathway in macrophage reprogramming and the progression of hepatocellular carcinoma (HCC) in patients with metabolic dysfunction-associated steatohepatitis (MASH). The key research objectives are to:...
- This federal Project Grant award, titled "SMALL LIVER CANCER: DEVELOPMENT OF A MULTI-LEVEL INTERVENTION TO IMPROVE ACCESS TO CURE (LIVER:CURE)", is funded by the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program. The $171,135 award will support Dr. Resmi Charalel's research to investigate barriers and facilitators to timely treatment for small hepatocellular carcinoma (HCC) patients. The project aims to develop Dr. Charalel's expertise in...